XML 21 R10.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting
 9 Months Ended
Oct. 03, 2025
Segment Reporting [Abstract]  
SEGMENT REPORTING SEGMENT REPORTING
We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our President and Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our President and Chief Executive Officer uses net income to monitor budget versus actual results for purposes of evaluating performance and to make decisions about the allocation of resources.
Our significant segment expenses that are regularly provided to our President and Chief Executive Officer and included in the measure of segment net income consist of consolidated expenses for our operational departments: drug discovery, development, and selling, general and administrative and other segment items.
The segment and consolidated net income, including significant segment expenses were as follows (in thousands):
 Three Months Ended September 30,Nine Months Ended September 30,
 2025202420252024
Revenues$597,755 $539,542 $1,721,463 $1,601,946 
Less:
Cost of goods sold18,574 17,328 57,216 56,251 
Drug discovery23,838 25,221 63,448 72,807 
Development
133,645 158,365 421,021 477,486 
Selling, general, and administrative
103,129 97,542 336,835 312,144 
Other segment items(1)
82,078 105,040 206,212 242,252 
Interest income
(15,922)(18,709)(51,787)(55,861)
Provision for income taxes
58,835 36,782 150,476 115,461 
Segment and consolidated net income$193,578 $117,973 $538,042 $381,406 
_________________
(1) Other segment items include stock-based compensation, impairment of long-lived assets, restructuring expenses, other research and development expenses, including the allocation of general corporate costs to research and development services and development cost reimbursements in connection with certain of our collaboration arrangements, and other expenses, net.
All of our long-lived assets are located in the U.S. See “Note 3. Revenues” for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.